Skip to main content
Premium Trial:

Request an Annual Quote

PROTEOMICS: Plexxikon Looks to Beat Syrrx, Pharma


Don’t tell Plexxikon there’s no money left in investors’ pockets. The Berkeley, Calif.-based company recently closed a $27 million funding round led by Walden International.

Founded in 1999 by a team of scientists with expertise in cell signaling proteins and their potential as drug targets, Plexxikon differentiates itself from structural proteomics competitors such as Syrrx, Structural Genomix, and big pharma companies by not pursuing a high-throughput crystallography approach.

With a first venture round of $8.2 million last year, Plexxikon began by focusing on four undisclosed protein families — presumably involved in cell signaling — and plans to add more families this year. “Choosing the subset of molecules to look at, the potential targets, is probably one of the more important [tasks],” says Jack Dixon, a member of the company’s scientific advisory board and professor in the biological chemistry department at the University of Michigan Medical School.

To design lead compounds against those targets, Plexxikon is combining x-ray crystallography, molecular modeling, and chemistry. First, Plexxikon scientists hope to identify chemical “scaffolds,” or molecules that bind to a wide range of members in a protein family. A promising scaffold could be developed into more selective and high-affinity drug leads. Plexxikon has an agreement with Scynexis, a Research Triangle Park, NC, company specializing in synthetic organic chemistry, for access to Scynexis’ compound synthesis technology.

— Julia Karow

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.